- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00353431
Evaluation of an Algorithm for Intensive s.c. Insulin Therapy in Emergency Room Patients With Hyperglycaemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
BACKGROUND: Prospective randomized trials have shown that near-normoglycemic blood glucose control using insulin infusions achieves a significant reduction in mortality of severely ill patients in intensive care units, of patients with acute myocardial infarction and with stroke. This implies that most severely ill patients with hyperglycemia should be treated with insulin to reach near-normoglycemia. However, this is not common practice today in emergency room admissions outside the intensive care unit, and strategies to achieve near-normoglycemia safely outside the ICU setting with s.c. injections (insulin infusions are too risky outside the ICU) have not been established.
AIM: To evaluate an insulin therapy algorithm using s.c. injections which permits effective and safe glycemic management of emergency room patients with hyperglycemia.
DESIGN: Randomized, controlled trial with an open intervention. Patients presenting with hyperglycemia on admission to the emergency room are randomized 1:1 either to conventional treatment (conventional insulin group) or to intensive treatment (intensive insulin group).
METHODS: 140 patients admitted to the medical emergency rooms of the University Hospital Basel and the Regional Hospital of Solothurn will be included and randomized as described above. All patients with plasma glucose levels exceeding 8.0 mmol/l will be included.
Exclusion criteria include severely immunocompromised patients, patients in shock, patients with terminal illnesses on palliative care, type 1 diabetes with or without ketoacidosis and patients which require intensive care unit (ICU) or cardial care unit (CCU) therapy.
PRIMARY ENDPOINT: Time in the glycaemic target range (5.5-7.0 mmol/l) during the period of observation of 48 hours (expected to be longer in the intensive insulin group)
SECONDARY ENDPOINTS: Time to reach the target range. Frequency of hypoglycaemia (plasma glucose < 3.8 mmol/l). Frequency of severe hypoglycaemia (plasma glucose < 2.5 mmol/l. Frequency of hypokalaemia.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Baselstadt
-
Basel, Baselstadt, Switzerland, 4031
- Division of Endocrinology, Diabetes & Clinical Nutrition, Dept of Internal Medicine,
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- all patients with hyperglycaemia (≥ 8.0 mmol/l) admitted to the medical emergency room.
- patients with presumed hospitalisation in ER or medical ward of more than 48 h duration.
Exclusion Criteria:
- patients in shock (defined as hypotension or shock index > 1 with oliguria, changed mental status and metabolic acidosis)
- patients with a terminal illness on palliative care
- patients with type 1 diabetes
- patients with insulin pump therapy
- patients with need for hospitalisation in the intensive or coronary care unit.
- patients with presumed hospitalisation shorter than 48 hours
- known pregnancy (in women with childbearing potential pregnancy test for exclusion mandatory)
- no informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Conventional insulin group: In the conventional insulin group only the meal-glucose adapted sliding scale at beginning is pre-determined. All adaptations of the insulin sliding scale remain upon the discretion of the treating physician. |
Comparison of a sliding scale with an intensive s.c.
scale
Other Names:
|
Experimental: 2
Intensive insulin therapy algorithm: The algorithm in the intensive insulin group contains four insulin resistance factors, depending on baseline features of the patients and on the changes of plasma glucose levels after insulin administration. Every two to four hours the plasma glucose level is measured and Insulin aspart (Novorapid®) is injected s.c. according to the scheme. If the patient is eating, the dose of Insulin aspart (NovoRapid®)is increased according to the amount of carbohydrate intake. |
Comparison of a sliding scale with an intensive s.c.
scale
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours
Time Frame: 48 h
|
Hours in which the plasma glucose was between 5.5 and 7.0 mmol/l (expected to be longer in the intensive insulin group)
|
48 h
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Reach the Target Range
Time Frame: 24 h
|
Hours needed to reach 5.5.-7.0 mmol/l (expected to be shorter in the intensive insulin group).
|
24 h
|
Frequency of Hypoglycemia
Time Frame: during observation of 48 hours
|
absolute number of participants with hypoglycemia (plasma glucose < 3.8 mmol/l) (safety endpoint, expected to be similar in the two groups)
|
during observation of 48 hours
|
Frequency of Severe Hypoglycaemia
Time Frame: during observation of 48 hours
|
Number of participants with severe hypoglycaemia (plasma glucose < 2.5 mmol/l) (safety endpoint, expected to be similar in the two groups)
|
during observation of 48 hours
|
Frequency of Hypokalaemia
Time Frame: during observation of 48 hours
|
Number of participants with hypokalaemia (potassium < 3.6 mmol/l, safety endpoint, expected to be similar in the two groups)
|
during observation of 48 hours
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ulrich Keller, MD, Prof, Division of Endocrinology, Diabetes & Clinical Nutrition, Dept of Internal Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EKBB13/06
- ISRCTN55224894 (Registry Identifier: Current Controlled Trials Database)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Novorapid ®, Novo Nordisk, Denmark
-
Karolinska InstitutetCompletedType 2 Diabetes Mellitus | Postprandial HyperglycemiaSweden
-
Chen Wei Ren, MDUnknownAcute Myocardial InfarctionChina
-
Rigshospitalet, DenmarkUnknownConstitutional Tall Stature
-
Charles University, Czech RepublicCompletedHyperglycemiaCzech Republic
-
University of GuadalajaraCompletedType 2 Diabetes MellitusMexico
-
Medical University of WarsawNot yet recruitingDiabetes Mellitus, Type 1 | Diabetes type1
-
Emory UniversityChildren's Research Oversight Committee FundsCompletedCardiopulmonary BypassUnited States
-
Woman's Health University Hospital, EgyptCompleted
-
University of AarhusCompletedTurner SyndromeDenmark
-
University of FloridaNovo Nordisk A/S; VA Office of Research and DevelopmentCompletedType 2 DiabetesUnited States